Abstract:Post-traumatic stress disorder (PTSD) is a common and disabling psychiatric disorder. Here we present findings from the first proteome-wide study of the postmortem PTSD brain. We performed tandem mass spectrometry on large cohort of donors (N = 66) in two prefrontal cortical areas and found differentially expressed proteins and co-expression modules disturbed in PTSD. Integrative analysis pointed to hsa-mir-589 as a regulatory miRNA responsible for disruptions in neuronal protein networks for PTSD, including the GABA vesicular transporter, SLC32A1. In addition, we identified significant enrichment of risk genes for Alzheimers Disease (N= 94,403), major depression (N = 807,553), and schizophrenia (N = 35,802) within PTSD co-expression protein modules, suggesting shared molecular pathology. Our findings highlight the altered proteomic landscape of postmortem PTSD brain and provide a novel framework for future studies integrating proteomic profiling with transcriptomics in postmortem human brain tissue. ### Competing Interest Statement JHK Financial Disclosure: Consultant (Note: The Individual Consultant Agreements listed below are less than $5000 per year): Aptinyx, Inc.; Atai Life Sciences; AstraZeneca Pharmaceuticals; Biogen, Idec,; MA; Biomedisyn Corporation; Bionomics, Limited (Australia); Boehringer Ingelheim International; Cadent Therapeutics, Inc.; Clexio Bioscience, Ltd.; COMPASS Pathways, Limited, UK; Concert Pharmaceuticals, Inc.; Epiodyne, Inc.; EpiVario, Inc.; Greenwich Biosciences, Inc.; Heptares Therapeutics, Limited (UK); Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Perception Neuroscience Holdings, Inc.; Spring Care, Inc.; Sunovion Pharmaceuticals, Inc.; Takeda Industries; Taisho Pharmaceutical Co., Ltd. Board of Directors: Freedom Biosciences, Inc. Scientific Advisory Board: Biohaven Pharmaceuticals; BioXcel Therapeutics, Inc. (Clinical Advisory Board); Cadent Therapeutics, Inc. (Clinical Advisory Board); Cerevel; Therapeutics, LLC; EpiVario, Inc.; Eisai, Inc.; Jazz Pharmaceuticals, Inc.; Lohocla Research Corporation; Novartis Pharmaceuticals Corporation; PsychoGenics, Inc.; RBNC Therapeutics, Inc.; Tempero Bio, Inc.; Terran Biosciences, Inc. Stock: Biohaven Pharmaceuticals; Sage Pharmaceuticals; Spring Care, Inc. Stock Options: Biohaven Pharmaceuticals Medical Sciences; EpiVario, Inc.; RBNC Therapeutics, Inc.; Terran Biosciences, Inc.; Tempero Bio, Inc. Income Greater than $10 000. Editorial Board: EditorBiological Psychiatry. Patents and Inventions: 1. Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of schizophrenia. US Patent #:5,447,948. 5 September 1995; 2. Vladimir, Coric, Krystal, John H, Sanacora, GerardGlutamate Modulating Agents in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: 15 July 2014. US Patent Application No. 15/695,164: Filing Date: 09/05/2017; 3. Charney D, Krystal JH, Manji H, Matthew S, Zarate C.Intranasal Administration of Ketamine to Treat Depression United States Patent Number: 9592207, Issue date: 3/14/2017. Licensed to Janssen Research & Development; 4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University Methods for Treating Suicidal Ideation, Patent Application No. 15/379,013 filed on 14 December 2016 by Yale University Office of Cooperative Research; 5. Arias A, Petrakis I, Krystal JH.Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. 2 April 2014. Filed by Yale University Office of Cooperative Research.; 6. Chekroud, A., Gueorguieva, R., & Krystal, JH. Treatment Selection for Major Depressive Disorder [filing date 3 June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by Yale University; 7. Gihyun, Yoon, Petrakis I, Krystal JHCompounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on 10 January 2017 by Yale University Office of Cooperative Research OCR 7088 US01; 8. Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing Depression or Other Mood Diseases. US Provisional Patent Application No. 62/719,935 filed on 20 August 2018 by Yale University Office of Cooperative Research OCR 7451 US01; 9. John Krystal, Godfrey Pearlson, Stephanie O'Malley, Marc Potenza, Fabrizio Gasparini, Baltazar Gomez- Mancilla, Vincent Malaterre. Mavoglurant in treating gambling and gaming disorders. US Provisional Patent Application No. 63/125,181filed on 14 December 2020 by Yale University Office of Cooperative Research OCR 8065 US00; NON Federal Research Support: AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant Center for Translational Neuroscience of Alcoholism [CTNA-4]; Novartis provides the drug, Mavoglurant, for research related to NIAAA grant Center for Translational Neuroscience of Alcoholism [CTNA-4]; Cerevel provides the drug PF-06412562 for A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia (1 U01 MH121766-01). ### Funding Statement The research reported here was supported by the Department of Veterans Affairs, Veteran Health Administration, VISN1 Career Development Award, a Brain and Behavior Research Foundation Young Investigator Award, and an American Foundation for Suicide Prevention Young Investigator Award to M.J.G. The proteomics was supported in part by the Yale/NIDA Neuroproteomics Centre (NIH DA018343) to M.J.G. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Yale School of Medicine gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

Perseverative behavior under uncertainty is enhanced by tryptophan depletion but diminished with subclinical obsessive–compulsive symptoms

Serotonin depletion impairs both Pavlovian and instrumental reversal learning in healthy humans

Effect of Tryptophan Depletion on Conditioned Threat Memory Expression: Role of Intolerance of Uncertainty

Serotonin Transporter Polymorphism Mediates Vulnerability to Loss of Incentive Motivation Following Acute Tryptophan Depletion

Perseveration and Shifting in Obsessive-Compulsive Disorder as a Function of Uncertainty, Punishment, and Serotonergic Medication

Probabilistic Reversal Learning under Acute Tryptophan Depletion in Healthy Humans: a Conventional Analysis

The effects of acute tryptophan depletion on costly information sampling: impulsivity or aversive processing?

Perseveration in a Spatial-Discrimination Serial Reversal Learning Task is Differentially Affected by MAO-A and MAO-B Inhibition and Associated with Reduced Anxiety and Peripheral Serotonin Levels

Tryptophan Depletion Promotes Habitual over Goal-Directed Control of Appetitive Responding in Humans.

Individual Differences in Threat Sensitivity Predict Serotonergic Modulation of Amygdala Response to Fearful Faces

5-HT Modulation by Acute Tryptophan Depletion of Human Instrumental Contingency Judgements

The Effects of Tryptophan Depletion on Cognitive and Affective Processing in Healthy Volunteers

Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour

The effects of acute tryptophan depletion on speech and behavioural mimicry in individuals at familial risk for depression

State and Trait Serotonin Variations Interact to Shape the Intrinsic Connectivity and Gradient Architecture of the Brain: a Combined TPH2 Genetics and Tryptophan Depletion Study

Acute Dietary Tryptophan Depletion Impairs Maintenance of "affective Set" and Delayed Visual Recognition in Healthy Volunteers

Neurocognitive performance in the context of acute symptom reduction in OCD: Treatment effects and the impact of BDNF

Reconciling the Role of Serotonin in Behavioral Inhibition and Aversion: Acute Tryptophan Depletion Abolishes Punishment-Induced Inhibition in Humans

Tryptophan Depletion Disrupts the Motivational Guidance of Goal-Directed Behavior As a Function of Trait Impulsivity

OCD PATIENTS SHOW INCREASED CERTAINTY SEEKING IN AN OPERANT OBSERVING RESPONSE TASK: A TRANSLATIONAL APPROACH

A Proteome-wide, Multi-Omics Analysis Implicates Novel Protein Dysregulation in Post-Traumatic Stress Disorder